Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity

Toxicology and Applied Pharmacology

Volumn 243, Issue 2, 2010, Pages 154-166

  Beger, Richard D ^a   Sun, Jinchun ^a   Schnackenberg, Laura K ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Heptatotoxicity; Metabolomics; Metabonomics; Nephrotoxicity

Indexed keywords

BIOLOGICAL MARKER; DRUG;

ANIMAL; CHEMICALLY INDUCED DISORDER; HUMAN; KIDNEY DISEASE; METABOLISM; METABOLOMICS; PHENOTYPE; REVIEW; TOXIC HEPATITIS;

ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HUMANS; KIDNEY DISEASES; METABOLOMICS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 77949417518     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.11.019     Document Type: Article

References (171)

1. Adamcova, M., Sterba, M., Simunek, T., Potacova, A., Popeloya, O., Mazurova, Y., Gersl, V., Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin. Drug Saf. 4 (2005), 457–472.
2. Amacher, D.E., Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul. Toxicol. Pharmacol. 27 (1998), 119–130.
3. Amar, P.J., Schiff, E.R., Acetaminophen safety and hepatotoxicity—where do we go from here?. Expert Opin. Drug Saf. 6 (2007), 341–355.
4. Anthony, M.L., Beddell, C.R., Lindon, J.C., Nicholson, J.K., Studies on the comparative toxicity of S-(1,2-dichlorovinyl)-L-cysteine, S-(1,2-dichlorovinyl)-L-homocysteine and 1,1,2-trichloro-3,3,3-trifluoro-1-propene in the Fischer 344 rat. Arch. Toxicol. 69 (1994), 99–110.
5. Anthony, M.L., Rose, V.S., Nicholson, J.K., Lindon, J.C., Classification of toxin-induced changes in 1H NMR spectra of urine using an artificial neural network. J. Pharm. Biomed. Anal. 13 (1995), 205–211.
6. Antti, H., Bollard, M.E., Ebbels, T.M., Keun, H., Lindon, J.C., Nicholson, J.K., Holmes, E., Batch statistical processing of 1H NMR-derived urinary spectral data. J. Chemometr. 16 (2002), 461–468.
7. Assfalg, M., Bertini, I., Colangiuli, D., Luchinat, C., Schäfer, H., Schütz, B., Spraul, M., Evidence of different metabolic phenotypes in humans. PNAS 105 (2008), 1420–1424.
8. Azmi, J., Griffin, J.L., Antti, H., Shore, R.F., Johansson, E., Nicholson, J.K., Holmes, E., Metabolic trajectory characterisation of xenobiotic-induced hepatotoxic lesions using statistical batch processing of NMR data. Analyst 127 (2002), 271–276.
9. Azmi, J., Griffin, J.L., Shore, R.F., Holmes, E., Nicholson, J.K., Chemometric analysis of biofluids following toxicant induced hepatotoxicity: a metabonomic approach to distinguish the effects of 1-naphthylisothiocyanate from its products. Xenobiotica 35 (2005), 839–852.
10. Bailey, W.J., Ulrich, R., Molecular profiling approaches for identifying novel biomarkers. Expert Opin. Drug Saf. 3 (2004), 137–151.
11. Beckwith-Hall, B.M., Nicholson, J.K., Nicholls, A.W., Foxall, P.J., Lindon, J.C., Connor, S.C., Abdi, M., Connelly, J., Holmes, E., Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins. Chem. Res. Toxicol. 11 (1998), 260–272.
12. Beger, R.D., Schnackenberg, L.K., Li, D., Dragan, Y., Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics 2 (2006), 125–134.
13. Beger, R.D., Hansen, D.K., Schnackenberg, L.K., Cross, B.M., Fatollahi, J.J., Lagunero, F.T., Sarnyai, Z., Boros, L.G., Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the (U-13C6)-D-glucose tracer in mice. Metabolomics, 2009.
14. Bernini, P., Bertini, I., Luchinat, C., Nepi, S., Saccenti, E., Schäfer, H., Schütz, B., Spraul, M., Tenori, L., Individual human phenotypes in metabolic space and time. J. Prot. Res. 8 (2009), 4264–4271.
15. Bertram, H.C., Malmendal, A., Petersen, B.O., Madsen, J.C., Pedersen, H., Nielsen, N.C., Hoppe, C., Mølgaard, C., Michaelsen, K.F., Duus, J.Ø., Anal. Chem. 79 (2007), 7110–7115.
16. Bessems, J.G.M., Vermeulen, N.P.E., Paracetamol (Acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues, and protective approaches. Crit. Rev. Toxicol. 31 (2001), 55–138.
17. Bleecker, M.L., The role of quantitative neurological examination in clinical neurotoxicology. Neurol. Clin. 18 (2000), 563–578.
18. Bobeldijk, I., Hekman, M., de Vries-van der Weij, J, Coulier, L., Ramaker, R., Kleemann, R., Kooistra, T., Rubingh, C., Freidig, A., Verheij, E., Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: compound class targeting in a metabolomics workflow. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 871 (2008), 306–313.
19. Bollard, M.E., Stanley, E.G., Lindon, J.C., Nicholson, J.K., Holmes, E., NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 18 (2005), 143–162.
20. Bollard, M.E., Keun, H.C., Beckonert, O., Ebbels, T.M., Antti, H., Nicholls, A.W., Shockcor, J.P., Cantor, G.H., Stevens, G., Lindon, J.C., Holmes, E., Nicholson, J.K., Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol. Appl. Pharmacol. 204 (2005), 135–151.
21. Boudonck, K.J., Mitchell, M.W., Nemet, L., Keresztes, L., Nyska, A., Shinar, D., Rosenstock, M., Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol. Pathol. 37 (2009), 280–292.
22. Bundy, J.G., Spurgeon, D.J., Svendsen, C., Hankard, P.K., Osborn, D., Lindon, J.C., Nicholson, J.K., Earthworm species of the genus Eisenia can be phenotypically differentiated by metabolic profiling. FEBS Lett. 521 (2002), 115–120.
23. Carrieri, D., McNeely, K., De Roo, A. C., Bennette, N., Pelczer, I., Dismukes, G. C. in press. Identification and quantification of water-soluble metabolites by cryoprobe-assisted nuclear magnetic resonance spectroscopy applied to microbial fermentation. Magn. Reson. Chem.
24. Chen, P., Liu, J., Metabonomics and diabetes mellitus. Adv. Ther. 24 (2007), 1036–1045.
25. Clayton, T.A., Lindon, J.C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.P., Le Net, J.L., Baker, J.D., Walley, R.J., Everett, J.R., Nicholson, J.K., Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440 (2006), 1073–1077.
26. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R., and Nicholson, J. K. in press. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. in press.
27. Coen, M., Lenz, E.M., Nicholson, J.K., Wilson, I.D., Pognan, F., Lindon, J.C., An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem. Res. Toxicol. 16 (2003), 295–303.
28. Constantinou, M.A., Papakonstantinou, E., Benakia, D., Spraul, M., Shulpis, K., Koupparis, M.A., Mikros, E., Application of nuclear magnetic resonance spectroscopy combined with principal component analysis in detecting inborn errors of metabolism using blood spots: a metabonomic approach. Anal. Chim. Acta 511 (2004), 303–312.
29. Craig, A., Sidaway, J., Holmes, E., Orton, T., Jackson, D., Rowlinson, R., Nickson, J., Tonge, R., Wilson, I., Nicholson, J., Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res. 5 (2006), 1586–1601.
30. Crockford, D.J., Keun, H.C., Smith, L.M., Holmes, E., Nicholson, J.K., Curve-fitting method for direct quatitation of compounds in complex biological mixtures using 1H NMR: application in metabonomic toxicology studies. Anal. Chem. 77 (2005), 4556–4562.
31. Crockford, D.J., Holmes, E., Lindon, J.C., Plumb, R.S., Zirah, S., Bruce, S.J., Rainville, P., Stumpf, C.L., Nicholson, J.K., Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem. 78 (2006), 363–371.
32. Daizo, A., Egashira, Y., Sanada, H., Suppressive effect of corn bran hemicellulose on liver injury induced by D-galactosamine in rats. Nutrition 21 (2005), 1044–1051.
33. Deming, S.N., Chemometrics: an overview. Clin. Chem. 32 (1986), 1702–1706.
34. Dhami, M.S., Drangova, R., Farkas, R., Balaza, T., Feuer, G., Decreased aminotransferase activity of serum and various tissues in the rat after cefazolin treatment. Clin. Chem. 25 (1979), 1263–1266.
35. Dufour, D.R., Lott, J.A., Nolte, F.S., Gretch, D.R., Koff, R.S., Seeff, L.B., Diagnosis and monitoring of hepatic injury: II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46 (2000), 2050–2068.
36. Dumas, M.E., Maibaum, E.C., Teague, C., Ueshima, H., Zhou, B., Lindon, J.C., Nicholson, J.K., Stamler, J., Elliott, P., Chang, Q., Holmes, E., Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP study. Anal. Chem. 78 (2006), 2199–2208.
37. Dumas, M.E., Barton, R.H., Tove, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J.C., Mitchell, S.C., Holmes, E., McCarthy, M.I., Scott, J., Gauguier, D., Nicholson, J.K., Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 12511–12516.
38. Dunn, W.B., Ellis, D.I., Metabolomics: current analytical platforms and methodologies. Trends Anal. Chem. 24 (2005), 285–294.
39. Ebbels, T., Keun, H., Beckonert, O., Antti, H., Bollard, M., Holmes, E., Lindon, J.C., Nicholson, J.K., Toxicity classification from metabonomic data using a density superposition approach: ‘CLOUDS’. Anal. Chim. Acta 490 (2003), 109–122.
40. Ebbels, T.M., Keun, H.C., Beckonert, O.P., Bollard, M.E., Lindon, J.C., Holmes, E., Nicholson, J.K., Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J. Proteome Res. 6 (2007), 4407–4422.
41. Edmondson, R.D., Vondriska, T.M., Biederman, K.J., Zhang, J., Jones, R.C., Zheng, Y., Allen, D.L., Xiu, J.X., Cardwell, E.M., Pisano, M.R., Ping, P., Protein kinase C epsilon signaling complexes include metabolism- and transcription/translation-related proteins: complimentary separation techniques with LC/MS/MS. Mol. Cell Proteomics 1 (2002), 421–433.
42. Espandiari, P., Zhang, J., Rosenzweig, B., Sun, J., Schnackenberg, L.K., Vaidya, V.S., Herman, E.H., Miller, T.J., Knapton, A., Beger, R.D., Thompson, K., Hanig, J., The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Tox. Sci. 99 (2007), 637–648.
43. Espandiari, P., Zhang, J., Schnackenberg, L.K., Miller, T.J., Knapton, A., Herman, E.H., Beger, R.D., Hanig, J.P., Age-related differences in susceptibility to toxic effects of valproic acid in rats. J. Appl. Toxicol. 28 (2008), 628–637.
44. Ferrara, C.T., Wang, P., Neto, E.C., Stevens, R.D., Bain, J.R., Wenner, B.R., Ilkayeva, O.R., Keller, M.P., Blasiole, D.A., Kendziorski, C., Yandell, B.S., Newgard, C.B., Attie, A.D., Genetic networks of liver metabolism revealed by integration of metabolomic and transcriptional profiling. PLoS Genet, e1000034, 2008, 4.
45. Fiehn, O., Metabolomics–The link between genotypes and phenotypes. Plant Mol. Biol. 48 (2002), 155–171.
46. Fiehn, O., Kristal, B., van Ommen, B., Sumner, L.W., Sansone, S.A., Taylor, C., Hardy, N., Kaddurah-Daouk, R., Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. OMICS 10 (2006), 158–163.
47. Fiehn, O., Robertson, D., Griffin, J., van der Werf, M., Nikolau, B., Morrison, N., Sumner, L. W., Goodacre, R., Hardy, N. W., Taylor, C., Fostel, J., Kristal, B., Kaddurah-Daouk, R., Mendes, P., van Ommen, B., Lindon, J. C., Sansone, S. A. in press. The metabolomics standards initiative (MSI). Metabolomics.
48. Gambus, A., Jones, R.C., Sanchez-Diaz, A., Kanemaki, M., van Deursen, F., Edmondson, R.D., Labib, K., GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks. Nat. Cell Biol. 8 (2006), 358–366.
49. Garrod, S., Bollard, M.E., Nicholls, A.W., Connor, S.C., Connelly, J., Nicholson, J.K., Holmes, E., Integrated metabonomic analysis of the multiorgan effects of hydrazine toxicity in the rat. Chem. Res. Toxicol. 18 (2005), 115–122.
50. Gartland, K.P., Bonner, F.W., Nicholson, J.K., Investigations into the biochemical effects of region-specific nephrotoxins. Mol. Pharmacol. 35 (1989), 242–250.
51. Gavaghan, C.L., Holmes, E., Lenz, E., Wilson, I.D., Nicholson, J.K., An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk:ApfCD mouse. FEBS Lett. 484 (2000), 169–174.
52. Ghiculescu, R.A., Kubler, P.A., Aminoglycoside-associated Fanconi syndrome. Am. J. Kidney Dis. 48 (2006), e89–93.
53. Gieger, C., Geistlinger, L., Altmaier, E., Hrabe de Angelis, M., Kronenberg, F., Meitinger, T., Mewes, H.W., Wichmann, H.E., Weinberger, K.M., Adamski, J., Illig, T., Suhre, K., Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. Genetic, 4, 2008, e1000282.
54. Gika, H.G., Theodoridis, G.A., Wingate, J.E., Wilson, I.D., Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6 (2007), 3291–3303.
55. Goodacre, R., Broadhurst, D., Smilde, A.K., Kristal, B.S., Baker, J.D., Beger, R., Bessant, C., Connor, S., Capuani, G., Craig, A., Ebbels, T., Kell, D.B., Manetti, C., Newton, J., Paternostro, G., Somorjai, R., Sjostrom, M., Trygg, J., Wulfert, F., Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 3 (2007), 231–241.
56. Griffin, J.L., Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 7 (2003), 648–654.
57. Griffin, J.L., Pole, J.C., Nicholson, J.K., Carmichael, P.L., Cellular environment of metabolites and a metabonomic study of tamoxifen in endometrial cells using gradient high resolution magic angle spinning 1H NMR spectroscopy. Biochim. Biophys. Acta 1619 (2003), 151–158.
58. Griffin, J.L., Nicholls, A.W., Daykin, C.A., Heald, S., Keun, H.C., Schuppe-Koistinen, I., Griffiths, J.R., Cheng, L.L., Rocca-Serra, P., Rubtsov, D.V., Robertson, D., Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments. Metabolomics 3 (2007), 179–188.
59. Gu, H., Chen, H., Pan, Z., Jackson, A.U., Talaty, N., Xi, B., Kissinger, C., Duda, C., Mann, D., Raftery, D., Cooks, R.G., Monitoring diet effects via biofluids and their implications for metabolomics studies. Anal. Chem. 79 (2007), 89–97.
60. Hanai, H., Ikuma, M., Sato, Y., Iida, T., Hosoda, Y., Matsushita, I., Nogaki, A., Yamada, M., Kaneko, E., Long-term effects of water-soluble corn bran hemicellulose on glucose tolderance in obese and non-obese patients, improved insulin sensitivity and glucose metabolism in obese subjects. Biosci. Biotechnol. Biochem. 61 (1997), 1358–1361.
61. Hardy, N.W., Taylor, C.F., A roadmap for the establishment of standard data exchange structures for metabolomics. Metabolomics 3 (2007), 243–248.
62. Harrigan, G.G., Yates, L.A., High-throughput screening, metabolomics and drug discovery. IDrugs 9 (2006), 188–192.
63. Harris, R.Z., Jang, G.R., Tsunoda, S., Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. 42 (2003), 1071–1088.
64. Haselden, J.N., Nicholls, A.W., Personalized medicine progresses. Nat. Med. 12 (2006), 510–511.
65. Heijne, W.H., Lamers, R.J., van Bladeren, P.J., Groten, J.P., van Nesselrooij, J.H., van Ommen, B., Profiles of metabolites and gene expression in rats with chemically induced hepatic necrosis. Toxicol. Pathol. 33 (2005), 425–433.
66. Holmes, E., Bonner, F.W., Sweatman, B.C., Lindon, J.C., Beddell, C.R., Rahr, E., Nicholson, J.K., Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol. Pharmacol. 42 (1992), 922–930.
67. Holmes, E., Tsang, T.M., Tabrizi, S.J., The application of NMR-based metabonomics in neurological disorders. NeuroRx 3 (2006), 358–372.
68. Holmes, E., Wilson, I.D., Nicholson, J.K., Metabolomic phenotyping in health and disease. Cell 134 (2008), 714–717.
69. Iles, R.A., Hind, A.J., Chalmers, R.A., Use of proton nuclear magnetic resonance spectroscopy in detection and study of organic acidurias. Clin. Chem. 31 (1985), 1795–1801.
70. Ishihara, K., Katsutani, N., Aoki, T., A metabonomics study of the hepatotoxicants galactosamine, methylene dianiline and clofibrate in rats. Basic Clin. Pharmacol. Toxicol. 99 (2006), 251–260.
71. Kaplowitz, N., Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 24 (2001), 483–490.
72. Kaplowitz, N., Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 (2005), 489–499.
73. Kaput, J., Perlina, A., Hatipoglu, B., Bartholomew, A., Nikolsky, Y., Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics 8 (2007), 369–390.
74. Keun, H.C., Antti, H., Bollard, M.E., Beckonert, O., Schlotterbeck, G., Senn, H., Niederhauser, U., Holmes, E., Lindon, J.C., Nicholson, J.K., Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem. Res. Toxicol. 15 (2002), 1380–1386.
75. Keun, H.C., Ebbels, T.M., Bollard, M.E., Beckonert, O., Antti, H., Holmes, E., Lindon, J.C., Nicholson, J.K., Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chem. Res. Toxicol. 17 (2004), 578–587.
76. Keun, H., Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109 (2006), 92–106.
77. Kucera, O., Cervinkova, Z., Lotkova, H., Krivakova, P., Rousar, T., Muzakova, V., Hezova, R., Kandar, R., Rudolf, E., Protective effect of S-adenosylmethionine against galactosamine-induced injury of rat hepatocytes in primary culture. Physiol. Res. 55 (2006), 551–560.
78. Lavine, B., Workman, J., Chemometrics. Anal. Chem. 80 (2008), 4519–4531.
79. Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998), 1200–1205.
80. Lee, W.M., Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology 40 (2004), 6–9.
81. Lehnert, W., Hunkler, D., Possibilities of selective screening for inborn errors of metabolism using high-resolution 1H-FT-NMR spectrometry. Eur. J. Pediatr. 145 (1986), 260–266.
82. Lenz, E.M., Nicholson, J.K., Wilson, I.D., Timbrell, J.A., A 1H NMR spectroscopic study of the biochemical effects of ifosfamide in the rat: evaluation of potential biomarkers. Biomarkers 5 (2000), 424–435.
83. Lenz, E.M., Bright, J., Knight, R., Wilson, I.D., Major, H., Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J. Pharm. Biomed. Anal. 35 (2004), 599–608.
84. Lenz, E.M., Bright, J., Knight, R., Wilson, I.D., Major, H., A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 129 (2004), 535–541.
85. Lenz, E.M., Bright, J., Knight, R., Westwood, F.R., Davies, D., Major, H., Wilson, I.D., Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10 (2005), 173–187.
86. Lenz, E.M., Wilson, I.D., Analytical strategies in metabonomics. J. Proteome Res. 6 (2007), 443–458.
87. Lewis, J.H., Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin. Pharm. 3 (1984), 128–138.
88. Lindon, J.C., Nicholson, J.K., Everett, J.R., NMR spectroscopy of biofluids. Webb, G.A., (eds.) Annual Review of NMR Spectroscopy, 1999, Academic Press, San Diego, 2–88.
89. Lindon, J.C., Nicholson, J.K., Holmes, E., Antti, H., Bollard, M.E., Keun, H., Beckonert, O., Ebbels, T.M., Reily, M.D., Robertson, D., Stevens, G.J., Luke, P., Breau, A.P., Cantor, G.H., Bible, R.H., Niederhauser, U., Senn, H., Schlotterbeck, G., Sidelmann, U.G., Laursen, S.M., Tymiak, A., Car, B.D., Lehman-McKeeman, L., Colet, J.M., Loukaci, A., Thomas, C., Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187 (2003), 137–146.
90. Lindon, J.C., Holmes, E., Bollard, M.E., Stanley, E.G., Nicholson, J.K., Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9 (2004), 1–31.
91. Lindon, J.C., Keun, H., Ebbels, T.M., Pearce, J.M., Holmes, E., Nicholson, J.K., The consortium for metabonomic toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6 (2005), 691–699.
92. Lindon, J.C., Nicholson, J.K., Holmes, E., Keun, H.C., Craig, A., Pearce, J.T., Bruce, S.J., Hardy, N., Sansone, S.A., Antti, H., Jonsson, P., Daykin, C., Navarange, M., Beger, R.D., Verheij, E.R., Amberg, A., Baunsgaard, D., Cantor, G.H., Lehman-McKeeman, L., Earll, M., Wold, S., Johansson, E., Haseldon, J.N., Kramer, K., Thomas, C., Lindberg, J., Schuppe-Koistinen, I., Wilson, I.D., Reily, M.D., Robertson, D.G., Senn, H., Krotzky, A., Kochhar, S., Powell, J., van der Ouderaa, F., Plumb, R., Schaefer, H., Spraul, M., Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol. 23 (2005), 833–838.
93. Ma, X., Idle, J.R., Krausz, K.W., Tan, D.X., Ceraulo, L, Gonzalez, F.J., Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J. Pineal Res. 40 (2006), 343–349.
94. Macpherson, N.A., Moscarello, M.A., Goldberg, D.M., Aminoaciduria is an earlier index of renal tubular damage than conventional renal disease markers in the gentamicin-rat model of acute renal failure. Clin. Invest. Med. 14 (1991), 101–110.
95. Moolenaar, S.H., Engelke, U.F., Wevers, R.A., Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann. Clin. Biochem. 40 (2003), 16–24.
96. Moore, T.J., Cohen, M.R., Furberg, C.D., Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch. Intern. Med. 167 (2007), 1752–1759.
97. Morrison, N., Bearden, D., Bundy, J.G., Collette, T., Currie, F., Davey, M.P., Haigh, N.S., Hancock, D., Jones, O.A.H., Rochfort, S., Sansone, S.A., Stys, D., Teng, Q., Field, D., Viant, M.R., Standard reporting requirements for biological samples in metabolomics experiments: environmental context. Metabolomics 3 (2007), 203–210.
98. Mortishire-Smith, R.J., Skiles, G.L., Lawrence, J.W., Spence, S., Nicholls, A.W., Johnson, B.A., Nicholson, J.K., Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chem. Res. Toxicol. 17 (2004), 165–173.
99. Mosca, P., Bonazzi, P., Novelli, G., Jezequel, A.M., Orlandi, F., In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br. J. Exp. Pathol. 66 (1985), 737–742.
100. Murray, M., Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab. 7 (2006), 67–81.
101. Murray, M., Petrovic, N., Cytochrome P450: decision-making tools for personalized therapeutics. Curr. Opin. Mol. Ther. 8 (2006), 480–486.
102. Nava, M., Romero, F., Quiroz, Y., Parra, G., Bonet, L., Rodriguez-Iturbe, B., Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am. J. Physiol. Renal Physiol. 279 (2000), F910–F918.
103. Nekvindova, J., Anzenbacher, P., Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes. Ceska Slov. Farm. 56 (2007), 165–173.
104. Nicholson, J.K., Lindon, J.C., Holmes, E., ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29 (1999), 1181–1189.
105. Nicholson, J.K., Connelly, J., Lindon, J.C., Holmes, E., Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1 (2002), 153–162.
106. Nicholson, J.K., Holmes, E., Wilson, I.D., Gut microbes, mammalian metabolism and personalized healthcare. Nat. Rev. Microbiol. 3 (2005), 2–8.
107. Nicholson, J., Keun, H., Ebbels, T., COMET and the challenge of drug safety screening. J. Proteome Res. 6 (2007), 4098–4099.
108. Niemann, C.U., Serkova, N.J., Biochemical mechanisms of nephrotoxicity: application for metabolomics. Exp. Opin. Drug Metab. Toxicol. 3 (2007), 527–544.
109. Nunes De Paiva, M.J., Pereira Bastos De Siqueira, M.E., Increased serum bile acids as a possible biomarker of hepatotoxicity in Brazilian workers exposed to solvents in car repainting shops. Biomarkers 10 (2005), 456–463.
110. Ohta, T., Yamasaki, S., Egashira, Y., Sanada, H., Antioxidative activity of corn bran hemicellulose fragments. J. Agric. Food Chem. 42 (1994), 653–656.
111. Pan, Z., Gu, H., Talaty, N., Chen, H., Shanaiah, N., Hainline, B.E., Cooks, R.G., Raftery, D., Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 387 (2006), 539–549.
112. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K., Breckenridge, A.M., Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329 (2004), 15–19.
113. Plumb, R.S., Granger, J.H., Stumpf, C.L., Johnson, K.A., Smith, B.W., Gaulitz, S., Wilson, I.D., Castro-Perez, J., A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst 130 (2005), 844–849.
114. Plumb, R.S., Johnson, K.A., Rainville, P.D., Smith, B.W., Wilson, I.D., Castro-Perez, J.M., Nicholson, J.K., UPLC/MS(E); a new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun. Mass Spectrom. 20 (2006), 1989–1994.
115. Plumb, R.S., Jones, M.D., Rainville, P.D., Nicholson, J.K., A rapid simple approach to screening pharmaceutical products using ultra-performance LC couple to time-of-flight mass spectrometry and pattern recognition. J. Chromatogr. Sci. 46 (2008), 193–198.
116. Plumb, R.S., Rainville, P.D., Potts, W.B., Johnson, K.A., Gika, E., Wilson, I.D., Application of ultra performance liquid chromatography-mass spectrometry to profiling rat and dog bile. J. Proteome Res. 8 (2009), 2495–2500.
117. Portilla, D., Li, S., Nagothu, K., Megyesi, J., Schnackenberg, L., Safirstein, R.L., Beger, R.D., Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 69 (2006), 2194–2204.
118. Raamsdonk, L.M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M.C., Berden, J.A., Brindle, K.M., Kell, D.B., Rowland, J.J., Westerhoff, H.V., van Dam, K., Oliver, S.G., A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 19 (2001), 45–50.
119. Reily, M.D., Robosky, L.C., Manning, M.L., Butler, A., Baker, J.D., Winters, R.T., DFTMP, an NMR Reagent for assessing the near-neutral pH of biological samples. JACS 126 (2006), 12360–12361.
120. Reo, N.V., NMR-based metabolomics. Drug Chem. Toxicol. 25 (2002), 375–382.
121. Robertson, D.G., Reily, M.D., Sigler, R.E., Wells, D.F., Paterson, D.A., Braden, T.K., Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 57 (2000), 326–337.
122. Robertson, D.G., Reily, M.D., Albassam, M., Dethloff, L.A., Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol. 1 (2001), 7–19.
123. Robertson, D.G., Metabonomics in toxicology: a review. Toxicol. Sci. 85 (2005), 809–822.
124. Sansone, S.A., Schober, D., Atherton, H.J., Fiehn, O., Jenkins, H., Rocca-Serra, P., Rubtsov, D.V., Spasic, I., Soldatova, L., Taylor, C., Tseng, A., Viant, M.R., and Oncology Working Group Members. Metabolomics standards initiative: ontology working group work in progress. Metabolomics 3 (2007), 249–256.
125. Rubtsov, D.V., Jenkins, H., Ludwig, C., Easton, J., Viant, M.R., Gunther, U., Griffin, J.L., Hardy, N., Proposed reporting requirements for the description of NMR-based metabolomics experiments. Metabolomics 3 (2007), 223–229.
126. Schnackenberg, L., Beger, R.D., Dragan, Y., NMR-based metabonomic evaluation of livers from rats chronically treated with tamoxifen, mestranol, and phenobarbital. Metabonomics 1 (2005), 87–94.
127. Schnackenberg, L.K., Jones, R.C., Thyparambil, S., Taylor, J.T., Han, T., Tong, W., Hansen, D.K., Fuscoe, J.C., Edmondson, R.D., Beger, R.D., Dragan, Y.P., An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS 10 (2006), 1–14.
128. Schnackenberg, L.K., Dragan, Y.P., Reily, M.D., Robertson, D.G., Beger, R.D., Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants. Metabolomics 2 (2007), 87–100.
129. Schnackenberg, L.K., Sun, J., Espandiari, P., Holland, R.D., Hanig, J., Beger, R.D., Metabonomics evaluations of age-related changes in the urinary compositions of male Sprague–Dawley rats and effects of data normalization methods on statistical and quantitative analysis. BMC Bioinformatics(Suppl. 7), 2007, S3.
130. Schnackenberg, L.K., Chen, M., Sun, J., Holland, R.D., Dragan, Y., Tong, W., Welsh, W., Beger, R.D., Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol. Appl. Pharmacol. 235 (2009), 25–32.
131. Sener, G., Sehirli, A.O., Altunbas, H.Z., Ersoy, Y., Paskaloglu, K., Arbak, S., Ayanoglu-Dulger, G., Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res. 32 (2002), 231–236.
132. Serkova, N.J., Christians, U., Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther. Drug Monit. 27 (2005), 733–737.
133. Sherman, K.E., Alanine aminotransferase in clinical practice. A review. Arch. Intern. Med. 151 (1991), 260–265.
134. Shi, C., Wu, C.Q., Cao, A.M., Sheng, H.Z., Yan, X.Z., Liao, M.Y., NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. Toxicol. Lett. 173 (2007), 161–167.
135. Slim, R.M., Robertson, D.G., Albassam, M., Reily, M.D., Robosky, L., Dethloff, L.A., Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol. Appl. Pharmacol. 183 (2002), 108–116.
136. Soga, T., Baran, R., Suematsu, M., Ueno, Y., Ikeda, S., Sakurakawa, T., Kakazu, Y., Ishikawa, T., Robert, M., Nishioka, T., Tomita, M., Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 281 (2006), 16768–16776.
137. Sumner, L.W., Amber, A., Barrett, D., Beale, M.H., Beger, R., Daykin, C.A., Fan, T.W.-M., Fiehn, O., Goodacre, R., Griffin, J.L., Hankemeier, T., Hardy, N., Harnly, J., Higashi, R., Kopka, J., Lane, A.N., Lindon, J.C., Marriott, P., Nicholls, A.W., Reily, M.D., Thaden, J.J., Viant, M.R., Proposed minimum reporting standards for chemical analysis. Metabolomics 3 (2007), 211–221.
138. Sun, J., Schnackenberg, L.K., Holland, R.D., Schmitt, T.C., Cantor, G.H., Dragan, Y.P., Beger, R.D., Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J. Chromatogr. B 871 (2008), 328–340.
139. Sun J., Schnackenberg, L. K., Beger, R. D. in press. Pharmacokinetic studies of acetaminophen and metabolites and their correlations with toxicity using metabonomics. Drug Metab. Lett.
140. Sun, J., Schnackenberg, L. K., Hansen, D. K., and Beger, R. D. submitted for publication. A study of valproic acid-induced endogenous and exogenous metabolite alterations using LC/MS-based metabolomics. Bioanalysis.
141. Suter, L., Babiss, L.E., Wheeldon, E.B., Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 11 (2004), 161–172.
142. Sysi-Aho, M., Katajamaa, M., Yetukuri, L., Oresic, M., Normalization method for metabolomics data using optimal selection of multiple internal standards. BMC Bioinformatics, 8, 2007, 93.
143. Tilson, H.A., Moser, V.C., Comparison of screening approaches. Neurotoxicology 13 (1992), 1–13.
144. Vaidya, V.S., Bonventre, J.V., Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin. Drug Metab. Toxicol. 2 (2006), 697–713.
145. van de Poll, M.C., Soeters, P.B., Deutz, N.E., Fearon, K.C., Dejong, C.H., Renal metabolism of amino acids: its role in interorgan amino acid exchange. Am. J. Clin. Nutr. 79 (2004), 185–197.
146. van der Werf, M.J., Takors, R., Smedsgaard, J., Nielsen, J., Ferenci, T., Portais, J.C., Wittmann, C., Hooks, M., Tomassini, A., Oldiges, M., Fostel, J., Sauer, U., Standard reporting requirements for biological samples in metabolomics experiments: microbial and in vitro biology experiments. Metabolomics 3 (2007), 189–194.
147. Wagner, S., Scholz, K., Donegan, M., Burton, L., Wingate, J., Völkel, W., Metabonomics and biomarker discovery: LC-MS metabolic profiling and constant neutral loss scanning combined with multivariate data analysis for mercapturic acid analysis. Anal. Chem. 78 (2006), 1296–1305.
148. Wagner, S., Scholz, K., Sieber, M., Kellert, M., Voelkel, W., Tools in metabonomics: an integrated validation approach for LC-MS metabolic profiling of mercapturic acids in human urine. Anal. Chem. 79 (2007), 2918–2926.
149. Walgren, J.L., Mitchell, M.D., Thompson, D.C., Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35 (2005), 325–361.
150. Walter-Sack, I., Klotz, U., Influence of diet and nutritional status on drug metabolism. Clin. Pharmacokinet. 31 (1996), 47–64.
151. Waner, T., Nyska, A., The toxicological significance of decreased activities of blood alanine and aspartate aminotransferase. Vet. Res. Commun. 15 (1991), 73–78.
152. Warrack, B.M., Hnatyshyn, S., Ott, K.H., Reily, M.D., Sanders, M., Zhang, H., Drexler, D.M., Normalization strategies for metabonomic analysis of urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (2009), 547–552.
153. Waters, N.J., Holmes, E., Williams, A., Waterfield, C.J., Farrant, R.D., Nicholson, J.K., NMR and pattern recognition studies on the time-related metabolic effects of -naphthylisothiocyante on liver, urine, and plasma in the rat: an integrative metabonomic approach. Chem. Res. Toxicol. 14 (2001), 1401–1412.
154. Waters, N.J., Waterfield, C.J., Farrant, R.D., Holmes, E., Nicholson, J.K., Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis. J. Proteome Res. 5 (2006), 1448–1459.
155. Williams, R.E., Jacobsen, M., Lock, E.A., 1H NMR pattern recognition and 31P NMR studies with D-serine in rat urine and kidney, time- and dose-related metabolic effects. Chem. Res. Toxicol. 16 (2003), 1207–1216.
156. Williams, R.E., Lenz, E.M., Evans, J.A., Wilson, I.D., Granger, J.H., Plumb, R.S., Stumpf, C.L., A combined 1H NMR and HPLC-MC-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed. Anal. 38 (2005), 465–471.
157. Williams, R.E., Lenz, E.M., Lowden, J.S., Rantalainen, M., Wilson, I.D., The metabonomics of aging and development in the rat: an investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. Mol. Biosyst. 1 (2005), 166–175.
158. Williams, R.E., Lenz, E.M., Rantalainen, M., Wilson, I.D., The comparative metabonomics of age-related changes in the urinary composition of male Wistar-derived and Zucker (fa/fa) obese rats. Mol. Biosyst. 2 (2006), 193–202.
159. Wilson, I.D., Nicholson, J.K., Castro-Perez, J., Granger, J.H., Johnson, K.A., Smith, B.W., Plumb, R.S., High resolution “ultra performance” liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 4 (2005), 591–598.
160. Wold, S., Sjöström, M., Chemometrics, present and future success. Chemometr. Intell. Lab. Syst. 44 (1998), 3–14.
161. Xin, H., Yi-Fei, G., Ke Y., Yi-Yu, C., Gas chromatography-mass spectrometry based on metabonomics study of carbon tetrachloride-induced acute liver injury in mice. Chinese, J. Anal. Chem. 35 (2007), 1736–1740.
162. Xu, F., Papanayotou, I., Putt, D.A., Wang, J., Lash, L.H., Role of mitochondrial dysfunction in cellular responses to S-(1,2-dichlorovinyl)-L-cysteine in primary cultures of human proximal tubular cells. Biochem. Pharmacol. 76 (2008), 552–567.
163. Yamada, R., Wakabayashi, Y., Iwashima, A., “In vivo” inhibition of murine liver aspartate aminotransferase by isoniazid. Acta Vitaminol. Enzymol. 6 (1984), 29–39.
164. Yamada, R.H., Wakabayashi, Y., Iwashima, A., Inhibition of serum aspartate aminotransferase induced by isoniazid administration in mice. Acta Vitaminol. Enzymol. 6 (1984), 289–293.
165. Yang, J., Xu, G., Zheng, Y., Kong, H., Wang, C., Zhao, X., Pang, T., Strategy for metabonomics research based on high-performance liquid chromatography and liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. A 1084 (2005), 214–221.
166. Yang, L., Xiong, A., He, Y., Wang, Z., Wang, C., Wang, Z., Li, W., Yang, L., Hu, Z., Bile acids metabonomic study on the CCL4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 21 (2008), 2280–2288.
167. Yap, I.K., Clayton, T.A., Tang, H., Everett, J.R., Hanton, G., Provost, J.P., Le Net, J.L., Charuel, C., Lindon, J.C., Nicholson, J.K., An integrated metabonomic approach to describe temporal metabolic disregulation induced in the rat by the model hepatotoxin allyl formate. J. Proteome Res. 5 (2006), 2675–2684.
168. Yokoyama, T., Banta, S., Berthiaume, F., Nagrath, D., Tompkins, R.G., Yarmush, M.L., Evolution of intrahepatic carbon, nitrogen, and energy metabolism in a D-galactosamine-induced rat liver failure model. Metab. Eng. 7 (2005), 88–103.
169. Zeisel, S.H., Da Costa, K.A., Franklin, P.D., Alexander, E.A., Lamont, J.T., Sheard, N.F., Beiser, A., Choline, an essential nutrient for humans. FASEB J. 5 (1991), 2093–2098.
170. Zhang, J., Herman, E.H., Robertson, D.G., Reily, M.D., Knapton, A., Ratajczak, H.V., Rifal, N., Honchel, R., Blanchard, K.T., Stoll, R.E., Sistare, F.D., Mechanisms and biomarkers of cardiovascular injury induced by phosphodiesterase inhibitor III SK&F 95654 in the spontaneously hypertensive rat. Toxicol. Pathol. 34 (2006), 1–12.
171. Zhou, Y., Vaidya, V.S., Brown, R.P., Zhang, J., Rosenweig, B.A., Thompson, K.L., Miller, T.J., Bonventre, J.V., Goering, P.L., Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chrominum. Toxicol. Sci. 101 (2008), 159–170.